EVP, Chief Financial Officer · REGENXBIO Inc. (RGNX)

Mitchell Chan

FY2024 is the first fiscal year CompBrief holds for Mitchell Chan as a named executive officer of REGENXBIO; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2024

$3,205,294

Salary $141,346Stock awards $749,991

3rd of 7 named executive officers at Regenxbio by FY2024 total.

7 named officers on file for REGENXBIO, FY2024

Mitchell Chan’s pay file — $29

  • 1 fiscal year of pay, line by line
  • 2 equity grants, each cited to its filing
  • RGNX’s disclosed peer group of 15 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how REGENXBIO’s whole pay program stands against its peers

  • REGENXBIO’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on RGNX→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 8, 2025 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Mitchell Chan’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Mitchell Chan compensation by year

REGENXBIO Summary Compensation Table · the one fiscal year held
In US dollars, as REGENXBIO reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2024
Salary$141,346
Bonus$0
Stock awards$749,991
Option awards$2,249,992
Non-equity incentive$56,921
Pension and deferred compensation$0
All other$7,044
Total$3,205,294

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: REGENXBIO Inc. DEF 14A filed April 8, 2025, accession 0000950170-25-052069, and prior-year filings. Open the filing on EDGAR.

How this page was built: the REGENXBIO Inc. filed document, accession 0000950170-25-052069. Every figure is read from that document and cited to the page and table it appears in. Filed April 8, 2025.

Equity holdings

unvested awards at FY2024 year-end
TypeUnvested unitsValue at year-endExercise price
RSU58,869$455,057—
Option289,362—$12.74

Per the Outstanding Equity Awards at Fiscal Year-End table in REGENXBIO Inc.'s FY2024 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

5 Form 4 lines since the FY2024 proxy (filed April 8, 2025)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2026-11-01Grant or award—24,305$0.00147,120
2026-09-01Tax withholding—4,902$9.32122,815
2026-01-06Grant or award—73,749$0.00127,717
2026-01-06Grant or award derivative—39,650$0.0039,650
2025-09-01Tax withholding—4,901$8.9353,968

The 5 most recent of 5 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

REGENXBIO’s named executive officers, FY2024

as the company reported each
Named executive officerRoleFY2024 total
Kenneth MillsFormer President and CEO$5,507,038
Curran SimpsonPresident and Chief Executive Officer$4,784,543
Mitchell Chan · this pageEVP, Chief Financial Officer$3,205,294
Olivier DanosEVP, Chief Scientific Officer$2,956,949
Patrick ChristmasEVP, Chief Strategy and Legal Officer$2,737,813
Stephen PakolaEVP, Chief Medical Officer$2,696,858
Vit VasistaFormer EVP, Chief Financial Officer$2,226,951

The full REGENXBIO compensation record

free company brief

This page is one person within REGENXBIO's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are REGENXBIO's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Mitchell Chan's compensation dossier · One-time report. No refunds.